June 2019 - Volume 3 - Issue - Contributor Index

Author:
Fabarius, A.

MARS: MUTATION-ADJUSTED RISK SCORE FOR ADVANCED SYSTEMIC MASTOCYTOSIS: S1611

Jawhar, M.; Schwaab, J.; Álvarez-Twose, I.; More

HemaSphere. 3:742-743, June 2019.

Author:
Fabbiano, F.

GILTERITINIB SIGNIFICANTLY PROLONGS OVERALL SURVIVAL IN PATIENTS WITH FLT3-MUTATED (FLT3MUT+) RELAPSED/REFRACTORY (R/R) ACUTE MYELOID LEUKEMIA (AML): RESULTS FROM THE PHASE 3 ADMIRAL TRIAL: S876

Perl, A.; Martinelli, G.; Cortes, J.; More

HemaSphere. 3:392-393, June 2019.

A DASATINIB-BLINATUMOMAB COMBINATION FOR THE FRONT-LINE TREATMENT OF ADULT PH+ ALL PATIENTS. PRELIMINARY RESULTS OF THE GIMEMA LAL2116 D-ALBA TRIAL; ON BEHALF OF GIMEMA ACUTE LEUKEMIA WORKING PARTY: S1617

Chiaretti, S.; Bassan, R.; Vitale, A.; More

HemaSphere. 3:746, June 2019.

Author:
Fabbri, A.

DOSE DENSE ABVD (DD-ABVD) AS FIRST LINE THERAPY IN EARLY-STAGE UNFAVOURABLE HODGKIN LYMPHOMA (CHL): RESULTS OF A PHASE II, PROSPECTIVE, MULTI-CENTER STUDY BY FONDAZIONE ITALIANA LINFOMI: PS1237

Mazza, R.; Spina, M.; Califano, C.; More

HemaSphere. 3:563-564, June 2019.

Author:
Fabbri, M.

A 14-GENE SIGNATURE ASSOCIATED TO CHOLESTEROL METABOLISM IDENTIFIES M1-LIKE TUMOR-INFILTRATING MACROPHAGES AND PREDICTS PATIENT SURVIVAL IN DIFFUSE LARGE B CELL LYMPHOMA: PF510

Vegliante, M. C.; De Summa, S.; Fabbri, M.; More

HemaSphere. 3:208, June 2019.

Author:
Fabian, F.

SAFETY AND EFFICACY OF TISAGENLECLEUCEL (CTL019) IN B ACUTE LYMPHOBLASTIC LEUKEMIA IN CHILDREN AND YOUNG ADULTS: ROBERT DEBRÉ AND SAINT LOUIS HOSPITALS EXPERIENCE: PS943

Dourthe, M. E.; Cabannes-Hamy, A.; Yakouben, K.; More

HemaSphere. 3:425, June 2019.

Author:
Fabienne, S.
Author:
Fabre, M.
Author:
Fabri, O.

DNA HYPERMETHYLATION EMERGES AS THE STRONGEST PREDICTOR FOR POOR OUTCOME AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN JUVENILE MYELOMONOCYTIC LEUKEMIA (JMML): PF677

Niemeyer, C. M.; Flotho, C.; Lipka, D. B.; More

HemaSphere. 3:292, June 2019.

Author:
Fabris, F.
Author:
Fabris, S.
Author:
Faça, V. M.
Author:
Facchetti, F.

PROGNOSTIC CORRELATION OF CELL-OF-ORIGIN AND MYC, BCL-2 AND BCL-6 STATUS IN HIV-ASSOCIATED DIFFUSE LARGE B-CELL LYMPHOMAS: PF529

Crucitti, L.; Rusconi, C.; Re, A.; More

HemaSphere. 3:217, June 2019.

Author:
Facchin, G.
Author:
Facchini, E.
Author:
Facco, M.

TARGETED ACTIVATION OF THE PROTEIN PHOSPHATASES SHP-1 AND PP2A ABROGATES CONSTITUTIVE ACTIVATION OF SURVIVAL PATHWAYS IN LARGE GRANULAR LYMPHOCYTE LEUKEMIA (LGLL): PS1145

Pagano, M. A.; Tibaldi, E.; Brunati, A. M.; More

HemaSphere. 3:518-519, June 2019.

Author:
Facon, T.

PHASE 3 RANDOMIZED STUDY OF DARATUMUMAB + BORTEZOMIB/THALIDOMIDE/DEXAMETHASONE (D-VTD) VERSUS VTD IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: PART 1 CASSIOPEIA RESULTS: S145

Moreau, P.; Attal, M.; Hulin, C.; More

HemaSphere. 3:24-25, June 2019.

IMPACT OF AGE ON EFFICACY AND SAFETY OF DARATUMUMAB IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE (D-RD) IN PATIENTS WITH TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): MAIA: PF592

Hulin, C.; Facon, T.; Kumar, S.; More

HemaSphere. 3:248-249, June 2019.

STEM CELL YIELD AND TRANSPLANTATION IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS RECEIVING DARATUMUMAB + BORTEZOMIB/THALIDOMIDE/DEXAMETHASONE (D-VTD): PHASE 3 CASSIOPEIA STUDY: PF598

Hulin, C.; Moreau, P.; Attal, M.; More

HemaSphere. 3:252, June 2019.

FASTER & SUSTAINED IMPROVEMENT IN HEALTH-RELATED QUALITY OF LIFE IN TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA PTS TREATED WITH DARATUMUMAB, LENALIDOMIDE & DEXAMETHASONE (D-RD) VS RD: MAIA: PF603

Perrot, A.; Facon, T.; Plesner, T.; More

HemaSphere. 3:255, June 2019.

EVALUATION OF AMG 420, AN ANTI-BCMA BISPECIFIC T-CELL ENGAGER (BITE®) IMMUNOTHERAPY, IN R/R MULTIPLE MYELOMA (MM) PATIENTS: UPDATED RESULTS OF A FIRST-IN-HUMAN (FIH) PHASE 1 DOSE ESCALATION STUDY: S825

Topp, M.; Duell, J.; Zugmaier, G.; More

HemaSphere. 3:365, June 2019.

Author:
Faderl, S.
Author:
Fadiloglu, E.

SINGLE CELL SIGNALING PHARMACODYNAMICS IN A PHASE 1B CLINICAL TRIAL OF THE AXL INHIBITOR BEMCENTINIB IN ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROME: PS999

Hellesøy, M.; Fagerholt, O. H. E.; Tislevoll, B. S.; More

HemaSphere. 3:449-450, June 2019.

MASS CYTOMETRY REVEAL EARLY SIGNALING RESPONSES TO INDUCTION THERAPY IN IMMUNOPHENOTYPICALLY DEFINED LEUKEMIC CELL SUBSETS THAT PREDICT SURVIVAL IN AML: S835

Tislevoll, B. S.; Fagerholt, O. H.E.; Hellesøy, M.; More

HemaSphere. 3:371-372, June 2019.

Author:
Fagerlie, S.
Author:
Fagnan, A.

GENETICS AND MODELING OF HUMAN ACUTE ERYTHROID LEUKEMIA: S113

Fagnan, A.; Piqué Borràs, Riera M.; Ignacimouttou, C.; More

HemaSphere. 3:8-9, June 2019.

Author:
Faict, S.
Author:
Faille, D.

FUNCTIONAL ASSAYS USING WASHED PLATELETS FOR HEPARIN-INDUCED THROMBOCYTOPENIA DIAGNOSIS: A RETROSPECTIVE STUDY COMPARING HEPARIN- INDUCED PLATELET ACTIVATION TEST VERSUS 14C-SEROTONIN RELEASE ASSAY: PS1495

Gkalea, V.; Gonthier, M.-C.; Gendron, N.; More

HemaSphere. 3:689, June 2019.

Author:
Faiman, B.
Author:
Fair, S.
Author:
Fajgenbaum, D.
Author:
Fakhfakh, Y.
Author:
Falanga, A.

ANTICOAGULANT THERAPY IN THROMBOCYTOPENIC PATIENTS WITH BLOOD CANCER AND CATHETER-RELATED VTE: RESULTS FROM A DELPHI CONSENSUS ON PLATELETS COUNT BELOW 50 X 109L: PF802

Napolitano, M.; avvisati, G.; Carpenedo, M.; More

HemaSphere. 3:353-354, June 2019.

THE COMBINATION OF LOW ADAMTS-13 ACTIVITY AND HIGH ANTI-ADAMTS13 ANTIBODIES AT REMISSION HIGHLY PREDICTS DISEASE RELAPSE IN PATIENTS WITH ACQUIRED TTP: A MULTI-INSTITUTIONAL STUDY: S1646

Schieppati, F.; Russo, L.; Marchetti, M.; More

HemaSphere. 3:761-762, June 2019.

Author:
Falantes, J.

REDUCED INTENSITY CONDITIONING AND AVOIDING USE OF BROAD SPECTRUM ANTIBIOTHERAPY ACTIVE AGAINST GRAM-NEGATIVE BACTERIA MIGHT HAVE A CUMULATIVE IMPACT IN REDUCING INTESTINAL MICROBIOTA MISBALANCE: PF757

Espigado, I.; Rodriguez, N.; Labrador, G.; More

HemaSphere. 3:332-333, June 2019.

Author:
Falantes, J. F.

ROLE OF MEASURABLE RESIDUAL DISEASE (MRD) IN REDEFINING COMPLETE RESPONSE (CR) IN ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML): RESULTS FROM THE PETHEMA-FLUGAZA PHASE III CLINICAL TRIAL: PF216

Paiva, B.; Martínez-Cuadrón, D.; Bergua, J. M.; More

HemaSphere. 3:59, June 2019.

Author:
Falay, M.
Author:
Falco, P.

SPARING STEROIDS IN ELDERLY INTERMEDIATE-FIT NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH A DOSE/SCHEDULE-ADJUSTED RD-R VS. CONTINUOUS RD: RESULTS OF RV-MM-PI-0752 PHASE III RANDOMIZED STUDY: PF586

Larocca, A.; Salvini, M.; Gaidano, G.; More

HemaSphere. 3:244, June 2019.

Author:
Falcone, A. P.

CARFILZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS: THE REAL LIFE EXPERIENCE OF RETE EMATOLOGICA PUGLIESE (REP): PF644

Mele, A.; Prete, E.; De Risi, C.; More

HemaSphere. 3:275-276, June 2019.

OPTIMIZATION OF TKI TREATMENT IN ELDERLY PATIENTS WITH PH+ CHRONIC MYELOID LEUKEMIA AND STABLE MR3.0 OR MR4.0: 1ST YEAR RESULTS OF THE ITALIAN MULTICENTRIC PHASE-III RANDOMIZED OPTKIMA STUDY: S882

Malagola, M.; Efficace, F.; Polverelli, N.; More

HemaSphere. 3:396-397, June 2019.

Author:
Falcone, M. A.

REAL-WORLD ITALIAN EXPERIENCE OF POMALIDOMIDE IN RELAPSED-REFRACTORY MYELOMA: RETROSPECTIVE MULTICENTER STUDY BY THE RETE EMATOLOGICA PUGLIESE AND BASILICATA: PB2130

Mele, G.; Pastore, D.; Di Renzo, N.; More

HemaSphere. 3:959, June 2019.

Author:
Falcone, U.
Author:
Falcucci, P.

THE BRAF INHIBITOR VEMURAFENIB COMBINED WITH RITUXIMAB PRODUCES A HIGH RATE OF DEEP AND DURABLE REMISSIONS IN RELAPSED OR REFRACTORY HAIRY CELL LEUKEMIA: UPDATED RESULTS OF A PHASE-2 TRIAL: S104

Tiacci, E.; De Carolis, L.; Simonetti, E.; More

HemaSphere. 3:3, June 2019.

Author:
Falini, B.

THE BRAF INHIBITOR VEMURAFENIB COMBINED WITH RITUXIMAB PRODUCES A HIGH RATE OF DEEP AND DURABLE REMISSIONS IN RELAPSED OR REFRACTORY HAIRY CELL LEUKEMIA: UPDATED RESULTS OF A PHASE-2 TRIAL: S104

Tiacci, E.; De Carolis, L.; Simonetti, E.; More

HemaSphere. 3:3, June 2019.

PROGNOSTIC VALUE OF CLONAL HEMATOPOIESIS-MUTATIONS DETECTED AT DIAGNOSIS IN ACUTE MYELOID LEUKEMIA PATIENTS WITH NORMAL KARYOTYPE: PF227

Caprioli, C.; Spinelli, O.; Salmoiraghi, S.; More

HemaSphere. 3:65-66, June 2019.

Author:
Falkenburg, F.
Author:
Falleh, S.
Author:
Fan, A.
Author:
Fan, B.

IVOSIDENIB (AG-120) INDUCES DURABLE REMISSIONS AND TRANSFUSION INDEPENDENCE IN PATIENTS WITH IDH1-MUTANT NEWLY-DIAGNOSED AML: UPDATED RESULTS FROM A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY: PS1025

Roboz, G. J.; DiNardo, C. D.; Stein, E. M.; More

HemaSphere. 3:461-462, June 2019.

IVOSIDENIB (AG-120) INDUCES DURABLE REMISSIONS AND TRANSFUSION INDEPENDENCE IN PATIENTS WITH IDH1-MUTANT RELAPSED/REFRACTORY MYELODYSPLASTIC SYNDROME IN A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY: PS1337

Foran, J. M.; DiNardo, C. D.; Watts, J. M.; More

HemaSphere. 3:610-611, June 2019.

Author:
Fan, H.
Author:
Fan, L.
Author:
Fan, X. Y.
Author:
Fan, Y.
Author:
Fan, Z.
Author:
Fanale, M.

THE ECHELON-2 TRIAL: RESULTS OF A RANDOMIZED, DOUBLE-BLIND PHASE 3 STUDY OF BRENTUXIMAB VEDOTIN AND CHP (A+CHP) VERSUS CHOP IN FRONTLINE TREATMENT OF PATIENTS WITH CD30+ PERIPHERAL T-CELL LYMPHOMAS: PS1070

Illidge, T.; Pro, B.; Trümper, L.; More

HemaSphere. 3:484-485, June 2019.

Author:
Fanci, R.

ISAVUCONAZOLE IN HEMATOLOGICAL PATIENTS: FINAL RESULTS OF A REAL-LIFE MULTICENTER SEIFEM (SORVEGLIANZA EPIDEMIOLOGICA DELLE INFEZIONI NELLE EMOPATIE) STUDY: PS1267

Cattaneo, C.; Gramegna, D.; Busca, A.; More

HemaSphere. 3:580-581, June 2019.

Author:
Fanciulli, M.

DEVELOPMENT AND OPTIMISATION OF A FULLY HUMAN FVIII MIMETIC BISPECIFIC ANTIBODY FOR PATIENTS WITH HAEMOPHILIA A: PF338

Wang, W.; Blackwood, J.; Magliozzi, R.; More

HemaSphere. 3:120-121, June 2019.

Author:
Fanelli, F.
Author:
Fang, C.-L.
Author:
Fang, M.-Y.

INCIDENCE, CLINICAL FEATURES, RISK FACTORS AND OUTCOMES OF REFRACTORY ACQUIRED IMMUNE THROMBOTIC THROMBOCYTOPENIC PURPURA: A CHINESE MULTI-CENTER EXPERIENCE: PF805

Gui, R.-Y.; Zhang, G.-C.; Wang, C.-C.; More

HemaSphere. 3:355, June 2019.

Author:
fang, X.
Author:
Fang, Y.
Author:
Fanhchaksai, K.
Author:
Fanin, R.

ELTROMBOPAG AS SECOND LINE THERAPY IN ADULT PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) IN ATTEMPT TO TREATMENT-FREE REMISSION. UPDATED RESULTS OF A PHASE II PROSPECTIVE STUDY BY GIMEMA GROUP: PF695

Lucchini, E.; Palandri, F.; Volpetti, S.; More

HemaSphere. 3:302, June 2019.

Show: